A disgruntled major shareholder has launched a $4.00 per share takeover bid for Cypress Bioscience, the US company best known for its fibromyalgia treatment Savella (milnacipran HCl).
A disgruntled major shareholder has launched a $4.00 per share takeover bid for Cypress Bioscience, the US company best known for its fibromyalgia treatment Savella (milnacipran HCl).
Ramius Value and Opportunity Advisers, a subsidiary of investment management business Ramius LLC, has sent a letter to the Cyprus...
Create an account to read this article
Already a subscriber?
With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.
Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.
